Meeting NewsVideo

VIDEO: AASLD to speak on Capitol Hill on the public health burden of NAFLD

WASHINGTON — In this exclusive video from The Liver Meeting 2017, Arun Sanyal, MD, FAASLD, from the Virginia Commonwealth University, discusses the public health burden of nonalcoholic fatty liver disease.

“It is really important to talk about this condition because a tremendous lack of awareness about fatty liver disease and it is our goal to increase awareness about this disease and to stimulate additional funding for research, to meet knowledge gaps, and to ultimate develop predictive and therapeutic paradigms that will help reduce the burden of this disease in our population,” Sanyal told Healio Gastroenterology and Liver Disease.

This week, AASLD will present a briefing on Capitol Hill to discuss NAFLD as a public health burden. – by Talitha Bennett

Disclosure: Sanyal reports he is on the advisory committee or review panel of Myers, Gilead, Genfit, Abbott, Ikaria, Pfizer, Novartis, Virology Education, Intercept and Sanofi; received consulting fees from Salix, Immuron, Exalenz, Nimbus, Genentech, Echosens, Takeda, Merck, Enanta, Zafgen, JD Pharma, Islet Sciences and ; received grants or research support Salix, Genentech, Intercept, Ikaria, Takeda, GalMed, Novartis, Gilead and Tobira; is an independent contractor for UpToDate and Elsevier; holds a management position with Sanyal Biotechnology; and is a stock shareholder of Exhalenz, Hemoshear, Akarna, and Genfit.

WASHINGTON — In this exclusive video from The Liver Meeting 2017, Arun Sanyal, MD, FAASLD, from the Virginia Commonwealth University, discusses the public health burden of nonalcoholic fatty liver disease.

“It is really important to talk about this condition because a tremendous lack of awareness about fatty liver disease and it is our goal to increase awareness about this disease and to stimulate additional funding for research, to meet knowledge gaps, and to ultimate develop predictive and therapeutic paradigms that will help reduce the burden of this disease in our population,” Sanyal told Healio Gastroenterology and Liver Disease.

This week, AASLD will present a briefing on Capitol Hill to discuss NAFLD as a public health burden. – by Talitha Bennett

Disclosure: Sanyal reports he is on the advisory committee or review panel of Myers, Gilead, Genfit, Abbott, Ikaria, Pfizer, Novartis, Virology Education, Intercept and Sanofi; received consulting fees from Salix, Immuron, Exalenz, Nimbus, Genentech, Echosens, Takeda, Merck, Enanta, Zafgen, JD Pharma, Islet Sciences and ; received grants or research support Salix, Genentech, Intercept, Ikaria, Takeda, GalMed, Novartis, Gilead and Tobira; is an independent contractor for UpToDate and Elsevier; holds a management position with Sanyal Biotechnology; and is a stock shareholder of Exhalenz, Hemoshear, Akarna, and Genfit.

    See more from The Liver Meeting